Cargando…

Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients

BACKGROUND: Circumsporozoite protein (CSP) has a central immune domain that includes short regions of repeating amino acid sequences. This immunodynamic region is an epitope of B cells that can elicit an immune response in human and laboratory animals. The aim of the present study was to express the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nateghpour, Mehdi, Etemadi, Soudabeh, Motevalli Haghi, Afsaneh, Eslami, Hamid, Mohebali, Mehdi, Farivar, Leila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620637/
https://www.ncbi.nlm.nih.gov/pubmed/34823591
http://dx.doi.org/10.1186/s40001-021-00607-6
_version_ 1784605268277985280
author Nateghpour, Mehdi
Etemadi, Soudabeh
Motevalli Haghi, Afsaneh
Eslami, Hamid
Mohebali, Mehdi
Farivar, Leila
author_facet Nateghpour, Mehdi
Etemadi, Soudabeh
Motevalli Haghi, Afsaneh
Eslami, Hamid
Mohebali, Mehdi
Farivar, Leila
author_sort Nateghpour, Mehdi
collection PubMed
description BACKGROUND: Circumsporozoite protein (CSP) has a central immune domain that includes short regions of repeating amino acid sequences. This immunodynamic region is an epitope of B cells that can elicit an immune response in human and laboratory animals. The aim of the present study was to express the recombinant PvCSP-VK210 antigen and evaluate it for assaying antibodies obtained during human P. vivax infection by Western blotting and indirect ELISA (enzyme-linked immunosorbent assay). METHOD: Genomic DNA of P. vivax was isolated from a blood sample of an Iranian person with vivax malaria, and by PCR, the fragment of the PvCSP-VK210 gene was amplified. The gene fragment was cut after gel purification by BamHI and HindIII enzymes and then cloned into pET28a expression vector. Finally, the recombinant pET28a was transformed into the E. coli BL21 (DE3) as the expression host. In order to produce His-tagged protein, the expression host was cultured in LB medium. The protein was purified by Ni–NTA columns and immobilized metal affinity chromatography, and after confirmation by Western blotting technique, was used as the antigen in the indirect ELISA test. RESULTS: The recombinant protein was expressed and purified as a 32-kDa protein. The sensitivity and specificity of the indirect ELISA test with the recombinant PvCSP-VK210 antigen were 61.42% and 97.14%, respectively, based on OD  =  0.313. Between the results of the microscopic test and the indirect ELISA test with the recombinant PvCSP-VK210 antigen there was a Kappa coefficient of 0.586. The positive and negative predictive value and validity of the ELISA test with the recombinant PvCSP-VK210 antigen were 95.55%, 71.57%, 79.28%, respectively. CONCLUSION: The sensitivity of the indirect ELISA method with the recombinant PvCSP-VK210 antigen was 61.42%, which is the first report from Iran.
format Online
Article
Text
id pubmed-8620637
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86206372021-11-29 Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients Nateghpour, Mehdi Etemadi, Soudabeh Motevalli Haghi, Afsaneh Eslami, Hamid Mohebali, Mehdi Farivar, Leila Eur J Med Res Research BACKGROUND: Circumsporozoite protein (CSP) has a central immune domain that includes short regions of repeating amino acid sequences. This immunodynamic region is an epitope of B cells that can elicit an immune response in human and laboratory animals. The aim of the present study was to express the recombinant PvCSP-VK210 antigen and evaluate it for assaying antibodies obtained during human P. vivax infection by Western blotting and indirect ELISA (enzyme-linked immunosorbent assay). METHOD: Genomic DNA of P. vivax was isolated from a blood sample of an Iranian person with vivax malaria, and by PCR, the fragment of the PvCSP-VK210 gene was amplified. The gene fragment was cut after gel purification by BamHI and HindIII enzymes and then cloned into pET28a expression vector. Finally, the recombinant pET28a was transformed into the E. coli BL21 (DE3) as the expression host. In order to produce His-tagged protein, the expression host was cultured in LB medium. The protein was purified by Ni–NTA columns and immobilized metal affinity chromatography, and after confirmation by Western blotting technique, was used as the antigen in the indirect ELISA test. RESULTS: The recombinant protein was expressed and purified as a 32-kDa protein. The sensitivity and specificity of the indirect ELISA test with the recombinant PvCSP-VK210 antigen were 61.42% and 97.14%, respectively, based on OD  =  0.313. Between the results of the microscopic test and the indirect ELISA test with the recombinant PvCSP-VK210 antigen there was a Kappa coefficient of 0.586. The positive and negative predictive value and validity of the ELISA test with the recombinant PvCSP-VK210 antigen were 95.55%, 71.57%, 79.28%, respectively. CONCLUSION: The sensitivity of the indirect ELISA method with the recombinant PvCSP-VK210 antigen was 61.42%, which is the first report from Iran. BioMed Central 2021-11-25 /pmc/articles/PMC8620637/ /pubmed/34823591 http://dx.doi.org/10.1186/s40001-021-00607-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nateghpour, Mehdi
Etemadi, Soudabeh
Motevalli Haghi, Afsaneh
Eslami, Hamid
Mohebali, Mehdi
Farivar, Leila
Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients
title Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients
title_full Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients
title_fullStr Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients
title_full_unstemmed Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients
title_short Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients
title_sort serological responses to a soluble recombinant circumsporozoite protein-vk210 of plasmodium vivax (rpvcsp-vk210) among iranian malaria patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620637/
https://www.ncbi.nlm.nih.gov/pubmed/34823591
http://dx.doi.org/10.1186/s40001-021-00607-6
work_keys_str_mv AT nateghpourmehdi serologicalresponsestoasolublerecombinantcircumsporozoiteproteinvk210ofplasmodiumvivaxrpvcspvk210amongiranianmalariapatients
AT etemadisoudabeh serologicalresponsestoasolublerecombinantcircumsporozoiteproteinvk210ofplasmodiumvivaxrpvcspvk210amongiranianmalariapatients
AT motevallihaghiafsaneh serologicalresponsestoasolublerecombinantcircumsporozoiteproteinvk210ofplasmodiumvivaxrpvcspvk210amongiranianmalariapatients
AT eslamihamid serologicalresponsestoasolublerecombinantcircumsporozoiteproteinvk210ofplasmodiumvivaxrpvcspvk210amongiranianmalariapatients
AT mohebalimehdi serologicalresponsestoasolublerecombinantcircumsporozoiteproteinvk210ofplasmodiumvivaxrpvcspvk210amongiranianmalariapatients
AT farivarleila serologicalresponsestoasolublerecombinantcircumsporozoiteproteinvk210ofplasmodiumvivaxrpvcspvk210amongiranianmalariapatients